Shareholders in BeiGene (NASDAQ:BGNE) have lost 54%, as stock drops 8.5% this past week

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and BeiGene (BGNE)

BeiGene: Hold Recommendation Amidst Mixed Financial Indicators and Robust Drug Pipeline Growth

BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

UPDATE 1-US FDA approves BeiGene's esophageal cancer therapy

First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

UPDATE 2-US FDA approves expanded use of BeiGene's blood cancer drug

Q4 2023 Zymeworks Inc Earnings Call

BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024